The Playground

  • Medical experts question Kamala Harris’ use of Pfizer pill for COVID treatment

    Medical experts question Kamala Harris’ use of Pfizer pill for COVID treatment
    Pfizer’s Paxlovid, the pill Harris used, is used to reduce severe symptoms among high-risk patients. Some medical experts questioned why it would be prescribed…

    Publicize a drug that the government paid a lot of your taxpayer money for and doctors don't want to prescribe

  • Not sure if this (or the original patent) was ever mentioned here:-

    Nano-Engineered Materials for LENR

    United States Patent Application: 0220130557 (

    Looking around I see Gregory Byron Goble first stumbled upon this before the USPTO published it. Now it is official with your post as the application date is today (28 Apr 2022).

    Klee Irwin has been talked about here on other threads about quantum gravity and such.... Quantum Gravity Research / Home of the emergence theory / Conference material by V Dubinko&al on LENR - Physics - LENR Forum ( but this patent is LENR related so good find.

    I will try and find a better home for it.

  • This is the new Danish study comparing the effectiveness against all-cause-death of the mRNA vaccines (Moderna/Pfizer), versus the adenovirus-vector (J&J/AZ):

    Randomised Clinical Trials of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific Effects? by Christine Stabell Benn, Frederik Schaltz-Buchholzer, Sebastian Nielsen, Mihai G. Netea, Peter Aaby :: SSRN

    And an article about the study; it's findings, what they may mean, and the weaknesses and strengths: Have People Been Given the Wrong Vaccine? ⋆ Brownstone Institute

  • This is the new Danish study comparing the effectiveness against all-cause-death of the mRNA vaccines (Moderna/Pfizer), versus the adenovirus-vector (J&J/AZ):

    Randomised Clinical Trials of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific Effects? by Christine Stabell Benn, Frederik Schaltz-Buchholzer, Sebastian Nielsen, Mihai G. Netea, Peter Aaby :: SSRN

    And an article about the study; it's findings, what they may mean, and the weaknesses and strengths: Have People Been Given the Wrong Vaccine? ⋆ Brownstone Institute

    And yet they approve this shit for under 6 year olds and younger and the media will bury the story or call the data misleading using Huxley's uncertainty narrative

  • Tennessee Governor Signs Medical Freedom Bill: Ivermectin Available via Pharmacy for COVID-19

    Senate Bill 2188 was signed by Tennessee Governor Bill Lee, making ivermectin accessible as a treatment for COVID-19 with no need for a prescription. TrialSite reported recently, that both the Senate and House voted in favor of the bill.

    According to the Tennessee law:

    “As enacted, authorizes a pharmacist to provide ivermectin to a patient, who is 18 years of age or older, pursuant to a valid collaborative pharmacy practice agreement containing a non-patient-specific prescriptive order and standardized procedures developed and executed by one or more authorized prescribers; enacts other related provisions. - Amends TCA Title 4; Title 14; Title 47; Title 53; Title 63; Title 68 and Title 71.

    Now, pharmacists in this state can offer ivermectin to any patient aged eighteen and above “pursuant to a valid collaborative pharmacy practice agreement containing a non-patient specific prescriptive order and standardized procedures developed and executed by one or more authorized prescribers.”

    This new law makes the drug available directly to a pharmacist without the need for even a physician’s prescription. The new law allows adults to go to the pharmacist and describe their symptoms and provide additional information about other conditions and medications to help the pharmacist determine the dosage

  • Which scientists exactly?

    Nearly every medical scientist, epidemiologist and doctor on earth agrees that the vaccines are effective. They give rock-solid proof. Graphs that show overwhelming evidence that the vaccines work, such as this one from Switzerland:

    Of course there a small number of scientists who disagree. If you read what they say, you will see that they are idiots and lunatics.

  • There are new worrying reports on quite strongly increasing numbers of hepatitis in young children around the globe, majority reported from UK, but more and more from other countries as well. None of the kids had been exposed to the wellknown hepatitis viruses A,B,C,D,E it seems, but analysis did show presence of adenoviruses. All cases had one thing in common: all kids had Covid-19, and none got a vaccination... so some deeper investigation required on the accurate biological mechanism.

    I just found this and thought you might be interested

    SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis

    SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis
    Autoimmune hepatitis episodes have been described following SARS-CoV-2 infection and vaccination but their pathophysiology remains unclear. Here, we report the…


    Background & Aims

    Autoimmune hepatitis episodes have been described following SARS-CoV-2 infection and vaccination but their pathophysiology remains unclear. Here, we report the case of a 52-year-old male, presenting with bimodal episodes of acute hepatitis, each occurring 2-3 weeks after BNT162b2 mRNA vaccination and sought to identify the underlying immune correlates. The patient received first oral budesonide, relapsed, but achieved remission under systemic steroids.


    Imaging mass cytometry for spatial immune profiling was performed on liver biopsy tissue. Flow cytometry was performed to dissect CD8 T cell phenotypes and identify SARS-CoV-2-specific and EBV-specific T cells longitudinally. Vaccine-induced antibodies were determined by ELISA. Data was correlated with clinical labs.


    Analysis of the hepatic tissue revealed an immune infiltrate quantitatively dominated by activated cytotoxic CD8 T cells with panlobular distribution. An enrichment of CD4 T cells, B cells, plasma cells and myeloid cells was also observed compared to controls. The intrahepatic underlying immune correlates. The patient received first oral budesonide, relapsed, but achieved remission under systemic steroids.



    COVID19 vaccination can elicit a distinct T cell-dominant immune-mediated hepatitis with a unique pathomechanism associated with vaccination induced antigen-specific tissue-resident immunity requiring systemic immunosuppression

  • Covid symptoms may return for some after taking Paxlovid antiviral pills

    Covid symptoms may return after taking Paxlovid antiviral pills, in rare cases
    The FDA is evaluating rare reports of "viral load rebound" after completing Paxlovid treatment.

    Pfizer’s antiviral pills are highly effective at keeping people with Covid out of the hospital, but there are growing reports that, in rare cases, patients treated for the coronavirus with Paxlovid can experience a second round of the disease shortly after recovering.

  • The united states healthcare ranking is 37th in industrialized world.

    Big Pharma Is Hijacking the Information Doctors Need Most

    Big Pharma Is Hijacking the Information Doctors Need Most
    Over the past few decades, the drug companies have taken over most of our clinical research.

    Back in 1982, when I first began my career as a family practitioner in a small town of Boston, I was confident that the care I’d provide would be as effective as the care patients receive anywhere in the world. At the time, the death rate for Americans was lower than that of comparable countries, resulting in 128,000 fewer deaths annually. Although healthcare was expensive—costing 2.3% more of our GDP than the average of 11 other wealthy countries—the rapid growth of HMOs and managed care plans promised to make our healthcare even more effective and efficient

    Over the ensuing four decades, however, the opposite has occurred. The same age-adjusted mortality rate has improved so much more in comparable countries that, by 2017, an excess 478,000 Americans were dying each year. This translates into an extra 1,300 deaths daily, equivalent to three jumbo jets crashing every day. The everyday poor health of Americans and the inability of our healthcare system to mitigate preventable deaths amounts to a crisis that dwarfs even the COVID-19 pandemic. And our excess spending has risen to 6.8 percent of GDP, or $1.5 trillion per year.

    This raises a key question: Why have so many smart, well-trained doctors stood by as American healthcare descended into a state of profound dysfunction?

    The answer lies in the gradual, nearly invisible commercial takeover of the medical “knowledge” that doctors are trained to trust.

  • If you read what they say, you will see that they are idiots and lunatics.

    The site you reference simply is cheating the data. The Swiss official report (A paper document with no graphs) already in autumn 2021 did show at least the same number of deaths among vaccinated.

    I linked it here several times - vaccine terrorists don't like real data..

  • Thanks, but in my opinion not an explanation for hepatitis as seen with all the unvaxxed infected kids…

  • SARS-CoV-2 Connection to Gut Health—Study Advances the Hypothesis that COVID-19 Severity Tied to the Microbiome

    Does SARS-CoV-2 infection somehow connect with gut health or the microbiome? TrialSite’s followed some emerging studies, including one at the Chinese University of Hong Kong (CUHK), implicating this relationship. Now a group of physician-investigators led by corresponding author Dr. Sabine Hazan of Malibu, California, report on an investigation comparing gut microbiome diversity and composition in COVID-19 positive patients whose symptoms range from asymptomatic to more severe conditions. Dr. Hazan, prominent in this early emergent but important field, hypothesized that low bacterial diversity and depletion of a bacteria called Bifidobacterium genera either prior to or after COVID-19 infection degrades proimmune function, thus leading to a more systematic and possibly severe SARS-CoV-2 infection. The authors declare that this specific dysbiosis pattern implies a susceptibility marker to symptomatic severity of COVID-19 and could be a target for intervention.

    TrialSite introduces this emergent but important topic captured in this latest study led by Dr. Sabine Hazan and colleagues. Dr. Hazan runs a private medical practice in Malibu, California, and also oversees research trial sites in Ventura, California, as well as Progenabiome, a research center defecated to microbiome research. Their study results were just published in the journal BMJ Open Gastroenterology.

    What is Bifidobacterium and what is its relevance?

    Bifidobacterium is the active ingredient of many probiotics and brings many health advantages. For example, in vitro studies evidence important benefits such as enhanced ATP production, immune modulation and competence, mucosal barrier integrity, restriction of bacterial adherence to and invasion of the intestinal epithelium as well as modulation of central nervous system activity report the authors led by Dr. Hazan.

    Moreover, they write that this “good” bacteria may possess anti-inflammatory properties, writing “Bifidobacterium animalis, B. longum and B. bifidum decrease the function of the ‘master switch’ proinflammatory tumor necrosis factor-α (TNF-α), increase the anti-inflammatory cytokine IL-10 and promote the Th1 while inhibiting the Th2 immune response. In a mouse model of inflammatory bowel disease (IBD), B. bifidum and B. animalis reduced proinflammatory cytokines and restored intestinal barrier integrity.”

    What happens to this good bacterium over time?

    According to Hazan and team, the abundance of this good bacteria, unfortunately, decreases as we grow older or gain an increased body mass index.

    What’s the connection of COVID-19 to Bifidobacterium?

    The authors propose that with SARS-CoV-2 infection comes an “immunologic coordination between the gut and lungs.”

    In fact, the authors point out that a growing body of evidence suggests that a healthy gut microbiome could be associated with decreased SARS-CoV-2 risk, such as mortality. In fact, they propose that probiotics are so helpful that they may actually serve as a prophylaxis to stave off the pathogen as well as become a form of treatment for SARS-CoV-2 or its associated secondary infections.

    Is there a dearth of serious inquiry into the gut microbiome?

    Yes. Out of 8,000 studies completed by February 2022 centering on COVID-19, just a few of them investigate the gut microbiome changes in SARS-CoV-2 infected patients. This is despite the fact that as Hazen and team share “an association between the status of the gut microbiome and outcome from this infection have been suggested.”

    What bacteria in the microbiome would be considered bad and associated with problems?

    For example, the authors share that Streptococcus, Rothia, Veilonella and Actinomyces genera are associated with inflammation. Meanwhile, abundances of select bacteria such as Collinsella aerofaciens, Collinsella tanakaei, Streptococcus infantis, and Morganella morganii are associated with fecal samples with high SARS-CoV-2 infectivity. Moreover, an increase in Lachnospiraceae and Enterobacterioaceae is associated with a greater risk of death and the need for artificial ventilation—dangerous conditions associated with COVID-19.

    What bacterial species are “good,” meaning they show the potential to protect against SARS-CoV-2 infection?

    Hazan and team write that “Parabacteroides merdae, Bacteroides stercoris, Alistipes onderdonkii, Lachnospiracea bacterium and F. prausnitzii “demonstrate protection against COVID-19. Lower amounts of Bifidobacterium implicate an increased risk of severity of COVID-19.

    What about long COVID-19—any association between gut health and COVID-risk?

    Yes. According to a study TrialSite covered at Chinese University Hong Kong (CUHK), there is a connection between microbiome health and Long-COVID, including lower levels of F. prausnitzii on admission.

    What kind of study did this team design?

    Registered in (NCT04031469), the study titled “A Non Interventional Pilot Study to Explore the Role of Gut Flora in Disease” involved an investigation into how the genetic information in a COVID-19 patient’s microbiome correlates to the information provided in surveys and medical records.

    Employing a cross-sectional design, the study team executed a shotgun next-generation sequencing on stool samples to evaluate gut microbiome composition and diversity, which were secured from both patients with SARS-CoV-2 PCR confirmed infections (presented to Dr. Hazan’s trial site facility called Ventura Clinical Trials) from March 2020 to October 2021 as well as SARS-CoV-2 PCR-negative exposed controls.

    What were the findings?

    The authors share that when comparing to the control group (n=20) severely symptomatic COVID-19 infected patients (n=28) had markedly less bacterial diversity (using the Shannon Index, p=0.0499 and the Simpson Index, p-0.0581 while positive patients in summary experienced lower relative abundances of Bifidobacterium (p<0.0001); Faecalibacterium (p=0.0077) and Roseburium (p=0.0327), while having increased Bacteroides (p=0.0075).

    What’s the net takeaway from this study?

    The investigators observed an inverse association between COVID-19 disease severity and abundance of the same bacterial.

    Thanks to the ongoing research of this study collaborative the group becomes more confident in a hypothesis that low bacterial diversity and waning of Bifidobacterium genera either before or after infection led to reduced proimmune function, thereby allowing SARS-CoV-2 infection to become symptomatic.

    This particular imbalance between the types of organism present in the patient’s natural microflora (especially in the gut) may contribute to a worsening of COVID-19. They suggest that these microbiome measures could become biomarkers helping to determine not only the risk for SARS-CoV-2 symptom severity but also suggest interventions before, during and after SARS-CoV-2 infection.

    Do these investigators disclose any interests?

    Yes. Dr. Hazan declared her business interest in Topelia Pty Ltd in Australia as well as an America subsidiary where she and an associated team are developing COVID-19 preventative/treatment options. Dr. Hazan is the founder of Progenabiome, a research institute dedicated to microbiome health. She also founded Ventura Clinical Trials, a trial site organization serving investigator-initiated and industry trials. Other investigators report interests in the various companies such as Australia’s Thomas Borody.

    About Progenabiome

    Based in Southern California, Progenabiome LLC is a sequencing research laboratory dedicated to advancing the work of the late Dr. Sydney Finegold, a pioneer in the field of microbiome research. The lab was founded by Dr. Sabine Hazan

  • tsn


    Iraqi Study on Anti-inflammatory Drug Colchicine, “Significantly” Reduced Severity of COVID-19 as an Add-on Treatment

    A Pre-proof research study was published earlier this month in the Annals of Medicine and Surgery Journal, named “Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe coronavirus disease-19 infection.” The study concluded that the anti-inflammatory drug, Colchicine when used as an add-on treatment for COVID-19, significantly reduced time to recovery for severe and moderate cases of COVID-19. While the study discloses that the drug did not lower death rates, it did reduce time with severe COVID-19 by five days, and moderate COVID-19 by two days. The randomized controlled open-label clinical trial included 160 hospitalized patients who were assessed for survival rate, time to cure in days, and side effects were assessed.

    Colchicine and Current NIH Evaluation

    The National Institutes of Health (NIH) describes colchicine and an anti-inflammatory drug used to treat a variety of conditions including gout, recurrent pericarditis, and familial Mediterranean fever. It mentions colchicine’s potential in reducing cardiovascular events for those diagnosed with coronary artery disease.

    Colchicine is thought to have multiple mechanisms of action. One of these is inhibiting inflammasome signaling. Inflammasomes are immune system receptors and sensors that induce inflammation in response to infectious microbes. Another action is decreasing the production of cytokines and reducing the chemotaxis (migration) of neutrophils. Neutrophils are the primary cells sent to inflammation sites during an innate immune response to tissue damage or infection, but can sometimes become uncontrolled or excessive. Finally, colchicine can decrease the production of cytokines, which are proteins crucial in controlling immune system cells and blood cells. However, COVID-19 infection can result in a “cytokine storm” that can further progress to extensive tissue damage, organ failure, and death.

    The NIH website states that for COVID-19 patients when colchicine is given early in the course of infection, “these mechanisms could potentially mitigate or prevent inflammation-associated manifestations of the disease. These anti-inflammatory properties coupled with the drug’s limited immunosuppressive potential, favorable safety profile, and widespread availability have prompted investigation of colchicine for the treatment of COVID-19.”

    Still, as of December 2021, the NIH recommends against colchicine for both hospitalized and non hospitalized patients with COVID-19. The NIH’s rationale cites several studies which determined “no significant difference” in its use. Here are the NIH’s evaluations of these studies.

    For Non-Hospitalized Patients:

    COLCORONA: the large RTC evaluating outpatients did not reach the primary endpoint of reducing hospitalization and death. However, a subset of COVID-19 patients were shown to have a “slight reduction in hospitalizations” among those who received colchicine.

    PRINCIPLE: randomized, open-label, adaptive platform trial was “stopped for futility.”

    For Hospitalized Patients

    RECOVERY Trial: Large randomized trial “demonstrated no benefit” with regard to 28-day mortality, or any secondary outcomes.

    Adding Colchicine to the Standard COVID-19 Therapy in Iraq

    The Iraqi research team was led by Faiq Isho Gorial, a subspecialist and assistant professor in Rheumatology in the Department of Medicine, at the University of Baghdad, Iraq. Gorial has also studied the effects of Niclosamide (NCS) as an add-on drug for standard care with COVID-19 patients. NCS is an anti-parasitic known for its antiviral potential and produced similar results to colchicine which was published as a pre-print on Medrxiv in 2021.

    TS News wants to inform readers that the standard of care practiced in this Iraqi trial is not similar to those practiced in the U.S. The authors will acknowledge this difference in their conclusion. Here are the differences.

    Iraqi Protocol:

    Acetaminophen: 500mg on need

    Vitamin C: 1000mg twice/day

    Zinc: 75–125?mg/day

    Vitamin D3: 5000IU/day

    Azithromycin: 250mg/day for 5 days

    Oxygen therapy/C-Pap: if needed

    Dexamethasone: 6?mg/day or methylprednisolone 40mg 2x/day, if needed

    According to the NIH website, the stance on nearly all of these therapeutics and nutritional supplements are against recommendation.

    “There is insufficient evidence to recommend either for or against the use of vitamin D for the prevention or treatment of COVID-19.”

    “There is insufficient evidence for the COVID-19 Treatment Guidelines Panel ? to recommend either for or against the use of zinc for the treatment of COVID-19.

    “The Panel recommends against using zinc supplementation above the recommended dietary allowance for the prevention of COVID-19, except in a clinical trial (BIII).”

    “There is insufficient evidence for the COVID-19 Treatment Guidelines Panel to recommend either for or against the use of vitamin C for the treatment of COVID-19 in non-critically ill patients.”

    “The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of chloroquine or hydroxychloroquine and/or azithromycin for the treatment of COVID-19 in hospitalized patients and in nonhospitalized patients.”

    In contrast, here are some graphics from the NIH which explain their protocol as COVID-19 disease progresses.

    U.S. Protocol (NIH)

    Non-hospitalized Patients

    Hospitalized Patients

    NIH States: “Remdesivir is the first drug approved by the FDA for the treatment of COVID-19 for adults and pediatric patients at least 12 years of age who are in the hospital. Remdesivir, also known as Veklury, is in a class of medications called antivirals. It works by stopping the virus from spreading in the body.”

    Remdesivir is manufactured by Pfizer, and clinical trials of its impact on reducing hospitalization and death do not always produce positive results. A study published in February 2022 in the Lancet, (called the DisCoVeRy trial) evaluated remdesivir’s efficacy concluded that “no clinical benefit was observed from the use of remdesivir in patients who were admitted to hospital for COVID-19, were symptomatic for more than 7 days, and required oxygen support.”

    Dexamethasone is a corticosteroid that “ improves clinical outcomes and reduces mortality in hospitalized patients with COVID-19 who require supplemental oxygen, presumably by mitigating the COVID-19-induced systemic inflammatory response that can lead to lung injury and multisystem organ dysfunction. ” according to the NIH. However, there is no observed benefit for those who do not require supplemental oxygen. They refer to two studies that provided evidence of dexamethasone’s efficacy. (This is the only drug that is used by the Iraqi study and is a part of the U.S. NIH-approved protocol.)

    The RECOVERY trial was a multicenter open-label trial in the UK with 6,425 patients. The results showed that for patients who needed mechanical ventilation or supplemental oxygen and were given dexamethasone in addition to standard of care, the mortality at 28 days was lower.

    The CoDEX trial, also multicenter and open-label in Brazil, evaluated dexamethasone in ventilated patients with acute respiratory distress syndrome (ARDS) from COVID-19. “The mean number of days alive and free from mechanical ventilation over 28 days was greater in the dexamethasone arm than in the standard care alone arm.” However, there were no differences between the arms in 28-day endpoints for mortality, ICU-free days, or duration of mechanical ventilation.

    Colchicine Add-On Results

    With an understanding of the stark differences in standards of care between Iraqi and U.S. healthcare providers, let’s examine what was found in the colchicine trial.

    The median age of participants was 49 [37–60.5] years, with 85 (53.1%) males. The four cohorts included Colchicine add-on for severe disease patients, colchicine add-on for moderately ill patients, and a control cohort for each disease severity. “There were no important or statistically significant differences in age, gender, and smoking habits between the 4 study groups… In addition, there was no difference in the relative frequency of selected comorbidities measured between study groups.”

    These comorbidities include:


    Diabetes Mellitus

    Ischemic Heart Disease





    Colchicine add-on treatment was associated with a significantly shorter time to cure by an average of 5 days in severe disease and 2 days in moderate disease. In addition, the Colchicine add-on significantly increased the risk of cure per unit of time by 2.69 times compared to controls. These were adjusted for disease severity, age, and time since the start of the disease to start of treatment.

    ““The acceleration in recovery, especially in severe patients treated with colchicine, is an indicator for the effectiveness of colchicine as anti-inflammatory, immunomodulatory and as cardiovascular protective agent as all these factors constitute the pillars for complicated ARDS in COVID19 cases.”

    “Moreover, the lower effectiveness in reducing time to recovery in moderate patients can endorse the theory that colchicine activity is mainly anti-inflammatory and immunomodulatory rather than an antiviral activity.”

    Final Thoughts

    In response to the results of the RECOVERY study mentioned by the NIH, Gorial et al, said “Although the death outcome is the same, our study revealed an obvious and statistically significant reduction in time to recovery in severe cases. The discrepancy in findings might be due to differences in the standard of care given to patients, their age or health status, and associated comorbidities between studies.”

    With only mild side effects consisting mostly of stomach upset and diarrhea, the authors determined that colchicine as an add-on treatment to standard of care “seems to play a potential role” in treating severe COVID-19 patients

  • Open Letter to Elon Musk

    Open Letter to Elon Musk

    Dear Elon,

    Congratulations on the acquisition of Twitter. We hope this will help put the world on track to be a better place.

    You stated that “Free speech is the bedrock of a functioning democracy and Twitter is the digital town square where matters vital to the future of humanity are debated…”

    We hope this is a promise to uphold the right to free speech and peaceful assembly on Twitter- both essential components of the democratic process.

    We hope that the dark days of witch-hunting and book-burning are behind us.

    Human nature is not always at its best. Deception is normal. Corruption is normal. Greed for money, power, and fame is normal. This is human nature. What is not normal is for society to accept the removal of the mechanism of error correction. We believe that with free speech, errors can be corrected and wrong-doers can be held accountable.

    Since the beginning of the COVID-19 pandemic, authority figures have spread false information unhindered. The fact of the matter is that the SARS-CoV-2 virus is not so novel and not as deadly to the general population as has been portrayed. The asymptomatic spread theory was a fear-mongering tool used to subdue the population. The unconstitutional mandates of lockdowns, masks, social distancing, testing and contact tracing, and mass vaccination were all ineffective in the management of this airborne virus and caused great harm to society. Those who dared to speak out against them were silenced and falsely accused of ‘misinformation’ while the public fell victim to relentless propaganda. The absurdity of these suppressions lies in the fact that much of what was regarded as ‘misinformation’ a year ago - is now accepted as truth by those who encouraged such sanctions.

    Throughout history, the wrong-doers were never those who spoke their truth at great personal cost. The wrong-doers were always those motivated to suppress the truth. What do they have to hide? What do they have to gain? How long should they be allowed to walk free without being questioned?

    We look forward to the changes you plan to implement on Twitter and ask you to consider adding the following points to your first board meeting agenda:




    Discuss the new features, open-source algorithms, spambots

    Clarify to the public your position on “authenticating all humans”. Does this merely refer to eliminating bots or does it include eliminating the possibility of anonymity? Historically, many injustices have been revealed by anonymous whistleblowers.

    PANDA is committed to open science, open society, and open debate. Societies cannot flourish without the courage to speak out and challenge existing assumptions.

    Thank you for playing your part. We will continue to play ours. We owe it to our fellow citizens.

    Kind regards,

    Abir Ballan (permanently suspended on Twitter TWICE)

    Member of the Executive Committee - Pandemics Data & Analytics

    Twitter: @abirballan, @Pandata19

    Facebook: @Pandata19

    About the author

    Abir Ballan has a Masters in Public Health and a background in psychology and education. She is appalled by how readily society has sacrificed its children during the Covid-19 pandemic. She is a member of the Executive Committee at PANDA (Pandemics—Data & Analytics)— Twitter, Facebook, Telegram, LinkedIn.

  • The government deserves blame here but it is the fear mongering media and the likes of rothwell and Huxley that contributed to this situation. They are the true death cult!

    NIH-Funded Study Reveals Suicides Among Young People Rising During Pandemic

    The National Institutes of Health (NIH) recently reported study results revealing that stresses associated with the pandemic may have contributed to more adolescent suicides. Funded by the NIH and covering 14 states, the authors found that although the number and proportion of youth suicide varied among individual states when all the states were considered together, researchers calculated an increase in the number of suicides among youth 10 to 19 years of age and in the proportion of youth suicides compared to the overall population.

    Support Needed Urgently

    Recently, appearing in a letter to JAMA Pediatrics, the study was led by Marie-Laure Charpignon, MSc., of the Massachusetts Institute of Technology, and colleagues. Funding was provided by NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Center for Advancing Translational Sciences.

    Study Background

    Last year, the American Academy of Pediatrics declared a state of emergency in response to the mental health challenges facing children, adolescents, and their families during the pandemic. Lockdown policies and masking in addition to a range of other changes were taking a toll on younger populations.

    As reported in a recent NIH press release, one study found that during the pandemic, the percentage of adolescents screening positive for symptoms of depression increased from 5% to 6.2%, and those screening positive for suicide risk increased from 6.1% to 7.1%.

    The present researchers obtained death record data from 14 states: Alaska, Arkansas, California, Colorado, Connecticut, Georgia, Indiana, Montana, Nebraska, New Jersey, Ohio, Oklahoma, Virginia, and Vermont. For each state, they compared the average of suicide counts from 2015 to 2019 to suicide counts from 2020, the first year of the pandemic.


    Compared to before the pandemic, five states had an increase in the number of youth suicides: Georgia (87.8 to 106), Indiana (62.8 to 83), New Jersey (32.4 to 37), Oklahoma (54.8 to 67), and Virginia (67.6 to 85). Combined, all states saw an increase in absolute suicide numbers (835.6 to 903).

    For the same time interval, researchers calculated the proportion of youth suicides among the total number of suicides in a state. Compared to before the pandemic, all the states with a higher number of youth suicides, plus California, also saw an increase in the proportion of suicides among youth during the pandemic, compared to the overall population: California (from 4.7% to 5.4%), Georgia (6% to 7.1%), Indiana (6.1% to 8.2%), New Jersey (4.6% to 5.8%), Oklahoma (6.9% to 8%), and Virginia (5.9% to 7.4%). For all 14 states combined, the proportion of youth suicides increased from 5.9% to 6.5%.

    Montana had a lower number of youth suicides and youth suicides as a percentage of total suicides. Alaska had a decrease in the proportion of youth suicides. There were no significant differences in adolescent suicides by either measure in Ohio, Connecticut, Colorado, or Arkansas.

    Youth Fare Worse than Adults

    The authors note that suicides among adults 35 and older declined during the pandemic and that those findings suggest the pandemic may have affected youth differently than adults.

    More Studies…& Action

    While the academic-focused authors recommend more research is needed to investigate the risk of youth suicides in addition to investigations into how the pandemic could influence suicide risk among youth, an urgent call for behavioral and mental health care becomes an obvious and urgent action.

    Lead Research/Investigator

    Marie-Laure Charpignon, MSc., of the Massachusetts Institute of Technology, and colleagues; Ms. Charpignon is a Ph.D. candidate at MIT

  • They might be rightwing republicans? Oh my

    Denmark becomes the first country to halt its Covid vaccination program


    Denmark has become the first country to halt its Covid vaccination program, saying it is doing so because the virus has been brought under control.

    "Spring has arrived, vaccine coverage in the Danish population is high, and the epidemic has reversed," Danish Health Authority said in a statement Wednesday announcing the move.

    Far from scrapping its vaccination program altogether, however, the Danish Health and Medicines Authority said there will probably be a need to vaccinate against Covid-19 again in the fall.

  • Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study

    Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study
    Omicron (B.1.1.529), a variant of SARS-CoV-2 is currently spreading globally as a dominant strain. Due to multiple mutations at its Spike protein, inc…



    Omicron (B.1.1.529), a variant of SARS-CoV-2 is currently spreading globally as a dominant strain. Due to multiple mutations at its Spike protein, including 15 amino acid substitutions at the receptor binding domain (RBD), Omicron is a variant of concern (VOC) and capable of escaping vaccine generated immunity. So far, no specific treatment regime is suggested for this VOC.


    The three-dimensional structure of the Spike RBD domain of Omicron variant was constructed by incorporating 15 amino acid substitutions to the Native Spike (S) structure and structural changes were compared that of the Native S. Seven phytochemicals namely Allicin, Capsaicin, Cinnamaldehyde, Curcumin, Gingerol, Piperine, and Zingeberene were docked with Omicron S protein and Omicron S-hACE2 complex. Further, molecular dynamic simulation was performed between Crcumin and Omicron S protein to evaluate the structural stability of the complex in the physiological environment and compared with that of the control drug Chloroquine.


    Curcumin, among seven phytochemicals, was found to have the most substantial inhibitory potential with Omicron S protein. Further, it was found that curcumin could disrupt the Omicron S-hACE2 complex. The molecular dynamic simulation demonstrated that Curcumin could form a stable structure with Omicron S in the physiological environment.


    To conclude, Curcumin can be considered as a potential therapeutic agent against the highly infectious Omicron variant of SARS-CoV-2.

  • Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2

    Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2
    Entry inhibitors against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are urgently needed to control the outbreak of coronavirus disease 2019…


    Entry inhibitors against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are urgently needed to control the outbreak of coronavirus disease 2019 (COVID-19). This study developed a robust and straightforward assay that detected the molecular interaction between the receptor-binding domain (RBD) of viral spike protein and the angiotensin-converting enzyme 2 (ACE2) receptor in just 10 min. A drug library of 1068 approved compounds was used to screen for SARS-CoV2 entry inhibition, and 9 active drugs were identified as specific pseudovirus entry inhibitors. A plaque reduction neutralization test using authentic SARS-CoV-2 virus in Vero E6 cells confirmed that 2 of these drugs (Etravirine and Dolutegravir) significantly inhibited the infection of SARS-CoV-2. With molecular docking, we showed that both Etravirine and Dolutegravir are preferentially bound to primary ACE2-interacting residues on the RBD domain, implying that these two drug blocks may prohibit the viral attachment of SARS-CoV-2. We compared the neutralizing activities of these entry inhibitors against different pseudoviruses carrying spike proteins from alpha, beta, gamma, and delta variants. Both Etravirine and Dolutegravir showed similar neutralizing activities against different variants, with EC50 values between 4.5 to 5.8 nM for Etravirine and 10.2 to 22.9 nM for Dolutegravir. These data implied that Etravirine and Dolutegravir may serve as general spike inhibitors against dominant viral variants of SARS-CoV-2.

  • Since the beginning of the COVID-19 pandemic, authority figures have spread false information unhindered.

    No, they have spread accurate, timely, science-based information. We know that because the methods they advocate and the vaccines they urge people to take have saved hundreds of thousands of lives in the U.S. alone. Nearly everyone who died after vaccines became available was not vaccinated. The data is absolutely irrefutable.

    Anti-vaxxers and people like you who spread lies about authority figures are spreading false information. You are a death cult. You are lunatics who claim that irrefutable data does not prove what any child can see it does. You are responsible for the deaths and ruined lives from long haul COVID. It is entirely your fault.

    Here is more irrefutable proof that the vaccines work. This is from the UK IAD, for Northern Ireland. This shows the importance of old people getting a booster.

  • International Team of Researchers Found Overlap with Code in SARS-CoV-2 & Moderna Patent

    In late February, the findings associated with a study led by a diverse group of medical researchers and scientists mostly from the U.S. but also Switzerland and India raised renewed suspicion, at least with some, that SARS-CoV-2, the virus behind COVID-19, may have been the result of some kind of gain-of-function lab experimentation. Led by corresponding author Kenneth Lundstrom, Ph.D., a molecular geneticist and CEO of Switzerland-based biotech, the study team’s results were published in Frontiers in Virology. The study team reported finding SARS-CoV-2 spike protein genetic material purportedly owned by Moderna. This small snippet of code mirrors a gene patented by mRNA COVID-19 vaccine maker Moderna three years prior: Moderna had partnered with the National Institutes of Health) on mRNA-based research prior to the pandemic. Did gain-of-function activity advance mutations? Scientists buying into these findings suggest the probability of such a pair is 1 in 3 trillion, yet critics have their doubts.

    Given the origin of SARS-CoV-2 has yet to be established, one would think that such study results led by credible, top scientists would have attracted more attention. Undoubtedly, pressures from high places seemed to emphasize the zoonotic theory, where the pathogen moved from bat to other animals to humans, perhaps via the Wuhan wet market or other means.

    But early on in the pandemic, within the NIH some prominent scientists raised concern that the pathogen looked engineered.

    However, an emergency late-night meeting led by Dr. Anthony Fauci led to a consensus among key scientists at the apex national research institution that the virus more than likely originated from naturally jumping species.

    TrialSite provides a brief summary of these study findings for those interested.

    Who are the researchers conducting this study?

    This scientific research was conducted by a multi-national, multi-discipline team of medical researchers led by corresponding author Kenneth Lundstrom, Ph.D., a molecular geneticist and CEO of a Switzerland-based biotech Pan Therapeutics. Other team members include:

    Bala Ambati, MD, Ph.D., an ophthalmologist and Research Professor at University of Oregon Knight Campus.

    Akhil Varshney, Ph.D., a Ramanujan Fellow, and scientist at Dr. Shroff’s Charity Eye Hospital

    Giorgio Palu, MD, Professor and Chair of Microbiology and Virology at University of Padova, School of Medicine.

    Bruce D. Uhal, Ph.D. Michigan State University, Department of Physiology

    Vladimir N. Uversky, Ph.D., DSc Professor, College of Medicine Molecular Medicine

    Adam M. Brufsky, MD, Ph.D., FACP Professor of Medicine University of Pittsburgh

    What did the researchers find?

    Interestingly, the scientists discovered the suspect snippet of code when investigating the part of SARS-CoV-2 that makes this particular pathogen so infectious—the distinctive furin cleavage site--distinguishing it from previous coronaviruses such as SARS-CoV-1 or MERS. The authors reported that this paired genetic sequence was patented by Cambridge, Massachusetts-based Moderna for cancer research.

    What is the probability that SARS-CoV-2 could have evolved naturally to this match?

    1 in 3 trillion, according to the scientists.

    What’s the context of this finding?

    The COVID-19 pathogen known as SARS-CoV-2 contains RNA, representing basically information or instructions necessary for its reproduction and thus survival. Based on 30,000 letters representing genetic code—again RNA—the international research team found that SARS-CoV-2 pairs with a sequence of 19 specific letters with a genetic segment owned by Moderna.

    It turns out that of these 19 shared letters of RNA, 12 are involved with COVID-19 unique furin cleavage location.

    The authors wrote that “Among the numerous point mutation differences between the SARS-CoV-2 and the bat RaTG13 coronavirus, only the 12-nucelotide furin cleavage site exceeds 3 nucleotides. A BLAST search revealed that 19 nucleotide portions of the SARS.CoV2 genome encompassing the furin cleavage site is a 100% complementary match to a codon-optimized proprietary sequence that is the reverse complement of the human mutS homolog (MSH3).”

    The study team secured University of Utah statistician, Dr. Jian Ying, for execution of probability analysis writing further:

    “The reverse complement sequence present in SARS-CoV-2 may occur randomly but other possibilities must be considered. Recombination in an intermediate host is an unlikely explanation. Single-stranded RNA viruses such as SARS-CoV-2 utilize negative-strand RNA templates in infected cells, which might lead through copy choice recombination with a negative sense SARS-CoV-2 RNA to the integration of the MSH3 negative strand, including the FCS, into the viral genome. In any case, the presence of the 19-nucleotide long RNA sequence including the FCS with 100% identity to the reverse complement of the MSH3 mRNA is highly unusual and requires further investigations.”

    Is there a widespread scientific consensus on these study results?

    No. Critics are many, and outspoken ones question the study conclusions; they point out that perhaps, the sequence pairing isn’t that rare. Some scientists argue the findings represent merely ‘quirky’ coincidence rather than a ‘smoking gun.’

    What’s the overlapping Moderna patent?

    Filed in 2016, the United States Patent Bancel et al (US Patent # 9,587,003 B2) was granted on March 7, 2017—see the link. Moderna successfully patented part of a gene known as MSH3 which has self-restorative properties involving damaged cells.

    What do the critics have to say?

    This news wasn’t carried by most American media, but UK’s MailOnline reported on the findings. Connor Boyd reported interactions with a few experts who raised serious doubts about the claims by the authors. For example, a Warwick University (UK) virologist acknowledged the findings were “interesting,” yet not sufficiently significant to imply the possibility of lab manipulation, telling MailOnline, “Were talking about a very, very, very small piece made up of 19 nucleotides.”

    Chalking it up to coincidence, “Sometimes these things happen fortuitously, sometimes it’s the result of convergent evolution (when organisms evolve independently to have similar traits to adapt to their environment).” He went on a “quirky observation, but I wouldn’t call it a smoking gun because it’s too small.”

    Moreover, a microbiologist at Reading University, Dr. Simon Clarke, suggested the finding wasn’t as rare as the study authors claim, telling the UK media, “…it’s an interesting coincidence but this surely entirely coincidental.” He makes this claim, declaring, “There can only be a certain number of [genetic combinations within] furin cleavage sites. They function like a lock and key in the cell, and the two only fit together in a limited number of combinations.”

    Yet can these critics be 100% confident the study author’s conclusions are incorrect? What about the math behind the 1 in 3 million probability of a match argument